Similar articles

• [Bortezomib in multiple myeloma patients after allogeneic stem cell transplantation].

  Vokurka S. Vokurka S. Klin Onkol. 2010;23(4):242-4. Klin Onkol. 2010. PMID: 20806822 Review. Czech.
• Bortezomib for post-allogeneic hematopoietic stem transplantation relapse and GVHD in multiple myeloma: a single institute experience.

  Kuroda J, Kobayashi T, Tsutsumi Y, Yamamoto M, Ohshiro M, Sasaki N, Shimura Y, Mizutani S, Nagoshi H, Kiyota M, Nakayama R, Uchiyama H, Matsumoto Y, Horiike S, Shimazaki C, Taniwaki M. Kuroda J, et al. Int J Hematol. 2010 Nov;92(4):669-72. doi: 10.1007/s12185-010-0709-3. Epub 2010 Oct 27. Int J Hematol. 2010. PMID: 20978877 No abstract available.
• NF-kappaB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145.

  Vodanovic-Jankovic S, Hari P, Jacobs P, Komorowski R, Drobyski WR. Vodanovic-Jankovic S, et al. Blood. 2006 Jan 15;107(2):827-34. doi: 10.1182/blood-2005-05-1820. Epub 2005 Sep 20. Blood. 2006. PMID: 16174760 Free PMC article.
• Bortezomib and extramedullary disease in multiple myeloma: the shine and dark side of the moon.

  Ali R, Ozkalemkas F, Ozkan A, Ozkocaman V, Ozcelik T, Ozan U, Kurt M, Tunali A. Ali R, et al. Leuk Res. 2007 Aug;31(8):1153-5. doi: 10.1016/j.leukres.2006.07.017. Epub 2006 Sep 1. Leuk Res. 2007. PMID: 16945413 No abstract available.
• [Current therapy for multiple myeloma].

  Swieboda-Sadlej A. Swieboda-Sadlej A. Pol Arch Med Wewn. 2005 Oct;114(4):1030-6. Pol Arch Med Wewn. 2005. PMID: 16789532 Review. Polish. No abstract available.